COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02931565
Recruitment Status : Completed
First Posted : October 13, 2016
Last Update Posted : June 6, 2019
Information provided by (Responsible Party):
Cyclerion Therapeutics

Brief Summary:

The objectives of this study are as follows:

In patients with primary Type I or II Achalasia, following a single 5-mg dose of IW-1701,

  • To assess the safety and tolerability
  • To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM)
  • To determine the pharmacokinetic (PK) parameters, Cmax, Tmax, and AUClast

Condition or disease Intervention/treatment Phase
Achalasia Drug: IW-1701 Drug: Matching Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-dose, Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 in Patients With Achalasia
Actual Study Start Date : February 2016
Actual Primary Completion Date : May 1, 2018
Actual Study Completion Date : May 1, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: IW-1701
Single 5-mg dose of IW-1701 administered orally
Drug: IW-1701
Placebo Comparator: Placebo
Matching placebo administered orally
Drug: Matching Placebo

Primary Outcome Measures :
  1. Treatment Emergent Adverse Events [ Time Frame: Within 28 days from dosing day (Day 1) ]
  2. Change in Integrated Relaxation Pressure (IRP) as measured by HRIM [ Time Frame: 1 day (Dosing day/ Day 1) ]
  3. Maximum observed plasma concentration [Cmax] [ Time Frame: Within 28 days of dosing day (Day 1) ]
    Maximum observed plasma concentration

  4. Area under the plasma concentration time curve during a dosing interval [AUC] [ Time Frame: Within 28 days of dosing day (Day 1) ]
    Area under the plasma concentration time curve during a dosing interval

  5. Time of maximum observed plasma concentration [Tmax] [ Time Frame: Within 28 days of dosing day (Day 1) ]
    Time of maximum observed plasma concentration

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient has a diagnosis of primary Type I or II achalasia.
  • Patient has no contraindications to the performance of the baseline and postdose HRIM procedures per Investigator discretion.

Exclusion Criteria:

  • Patient has had any prior esophageal, periesophageal, or gastric surgery, or treatment with sclerosing agent.
  • More than 1 pneumatic dilation procedure to a diameter of >2 cm in their lifetime.
  • Pneumatic dilation procedure to a diameter of >2 cm within 1 year prior to randomization. Prior bougie dilation(s) or pneumatic dilation(s) ≤ 2 cm are allowed.
  • Prior esophageal injection of botulinum toxin (Botox) within 6 months prior to randomization or more than 2 esophageal Botox injection procedures in their lifetime.
  • Patients with malignant or premalignant esophageal lesions.
  • Patient has taken any drug that can affect GI motility in the 72 hours before Check-in through Discharge from the clinic.
  • Other exclusion criteria specified in the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02931565

Layout table for location information
United States, Connecticut
Connecticut Clinical Research Foundation, Gastroenterology Institute
Bristol, Connecticut, United States, 06010
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University in St. Louis - School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Utah
University of Utah School of Medicine, Division of Gastroenterology, Hepatology & Nutrition
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
Cyclerion Therapeutics
Layout table for additonal information
Responsible Party: Cyclerion Therapeutics Identifier: NCT02931565    
Other Study ID Numbers: C1701-201
First Posted: October 13, 2016    Key Record Dates
Last Update Posted: June 6, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Esophageal Achalasia
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases